Results 131 to 140 of about 5,710 (181)

Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study. [PDF]

Lipids Health Dis
Kafol J, Fras Z, Novakovic M, Sperling LS, Cevc M, Krevel B, Kafol L, Kelenc A, Kepic K, Vrbinc K, Svarc M, Groselj U, Jug B.   +12 more
europepmc   +1 more source

Safety and efficacy of low-density lipoprotein-lowering drugs in the elderly: a network meta-analysis of randomized controlled trials. [PDF]

J Geriatr Cardiol
Niaga KJK, Supinto PA, Tjandra KC, Martin A, Drew C, Seno KHNH, Felix, Nugraha LAK, Tantowi F.   +8 more
europepmc   +1 more source

Clinical observation of renal artery stenosis treated with PCSK9 inhibitor. [PDF]

BMC Cardiovasc Disord
Zhao F, Gao Q, Jiang B, Li H, Wu Y, Yang W.   +5 more
europepmc   +1 more source

LDL-C target attainment and treatment costs in high-risk and very-high-risk patients with or without bempedoic acid: A Spanish cohort simulation. [PDF]

PLoS One
Cosin-Sales J, Abad-Sazatornil MR, Martín-Conde JA, Alonso Iglesias E, Mostaza Prieto JM.   +4 more
europepmc   +1 more source

From trial population to treated population: why EU-eligible subgroup analyses matter for anti-amyloid immunotherapy. [PDF]

J Prev Alzheimers Dis
Grimmer T.
europepmc   +1 more source

The Evolving Role of Coronary Artery Imaging in Assessing Cardiovascular Risk from Lipoprotein(a). [PDF]

Curr Atheroscler Rep
Savides MT, Bhatia HS, Kuznetsova I, Wilkinson MJ.   +3 more
europepmc   +1 more source

Advanced therapy in familial hypercholesterolemia. [PDF]

Can Fam Physician
Gao E, Brunham LR, Goldman RD.
europepmc   +1 more source

Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis.

JAMA Netw Open
Kellogg C, Badillo Goicoechea E, Kim DD, Yaghi S, Chaturvedi S, Mehendale R, Orjuela K, Kass-Hout T, Morsi RZ, Morales J, Singh E, Jhaveri A, Prabhakaran S, Smith MM, Brorson JR, Golani S, Mazuera S, Kang R, Eltatawy A, Pillajo J, Siegler JE.   +20 more
europepmc   +1 more source